Inflammatory Cytokines Measured in Infants Born to Preterm Preeclamptic Mothers
|
By LabMedica International staff writers Posted on 29 Nov 2021 |

Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)
Preeclampsia is both a vascular and inflammatory disorder. The pathophysiology of preeclampsia is complex and rooted in the interplay between maternal and placental factors with the key characteristics of maternal inflammation and vascular etiologies.
The maternal pathophysiology impacts fetal physiology through the filter of the placenta. Triggers of the fetal inflammatory response are not completely understood, as there is contradictory evidence as to whether cytokines directly cross the placenta-blood barrier and emerge on the fetal side or if the fetal inflammatory response is indirectly triggered.
Clinical Scientists at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) conducted a prospective inceptional cohort study of preterm preeclampsia from July 1, 2010, through June 30, 2012. Eighty-one maternal-newborn dyads were examined. Placentas were analyzed for inflammatory and vascular pathologies. Neurodevelopmental assessment of infants utilizing the Pediatric Stroke Outcome Measure (PSOM) was conducted at 6-month corrected gestational age.
Maternal venous blood samples were collected at time of enrollment and within two hours after delivery. Fetal cord blood venous samples were obtained immediately after delivery by trained perinatal nurses with experience in venous cord blood collection. Platelet-poor plasma was aliquoted, frozen, and sent for cytokine analysis (IL-1β, IL-6, IL-8, and TNF-α) via the Luminex multicode assay platform (Luminex Corp, Austin, TX, USA). Placenta analysis assessments were conducted by a placental pathologist.
The investigators reported that worse neurological outcomes were not associated with elevated maternal / fetal cytokines. Early preterm birth (gestational age ≤ 32 weeks) was associated with worse neurological outcomes at 6-months regardless of maternal/ fetal cytokine levels, placental pathology, or cranial ultrasound findings (OR 1.70). When correcting for gestational age, elevated IL-6 approached significance as a predictor for worse developmental outcome (OR 1.025 ). Pathological evidence of maternal malperfusion and worse outcomes were noted in early preterm, although the sample size was small. When chronic villitis was present (N = 5), higher maternal levels of IL-6 (N = 3; 60%) were usually present rather than in fetal cord blood. Although only three cases of histologic fetal inflammatory response were seen, both IL-6 and IL-8 were elevated in the fetal cord blood (N = 2; 67%), but not elevated in maternal samples.
The authors concluded that their study supports the distinction that 32-weeks gestational age (‘moderate preterm) is a turning point for improved neurological outcomes. They found that cranial ultrasounds were unhelpful in predicting risk in this pre-eclamptic population. The data suggest that maternal placental malperfusion at earlier gestational age may be an underlying factor associated with poor neurological outcomes, although more robust studies are warranted. Neither elevated cytokines nor “male disadvantage” was associated with adverse neurological outcomes. The study was published on November 15, 2021 in the journal PloS One.
Related Links:
University of Colorado Anschutz Medical Campus
Luminex Corp
The maternal pathophysiology impacts fetal physiology through the filter of the placenta. Triggers of the fetal inflammatory response are not completely understood, as there is contradictory evidence as to whether cytokines directly cross the placenta-blood barrier and emerge on the fetal side or if the fetal inflammatory response is indirectly triggered.
Clinical Scientists at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) conducted a prospective inceptional cohort study of preterm preeclampsia from July 1, 2010, through June 30, 2012. Eighty-one maternal-newborn dyads were examined. Placentas were analyzed for inflammatory and vascular pathologies. Neurodevelopmental assessment of infants utilizing the Pediatric Stroke Outcome Measure (PSOM) was conducted at 6-month corrected gestational age.
Maternal venous blood samples were collected at time of enrollment and within two hours after delivery. Fetal cord blood venous samples were obtained immediately after delivery by trained perinatal nurses with experience in venous cord blood collection. Platelet-poor plasma was aliquoted, frozen, and sent for cytokine analysis (IL-1β, IL-6, IL-8, and TNF-α) via the Luminex multicode assay platform (Luminex Corp, Austin, TX, USA). Placenta analysis assessments were conducted by a placental pathologist.
The investigators reported that worse neurological outcomes were not associated with elevated maternal / fetal cytokines. Early preterm birth (gestational age ≤ 32 weeks) was associated with worse neurological outcomes at 6-months regardless of maternal/ fetal cytokine levels, placental pathology, or cranial ultrasound findings (OR 1.70). When correcting for gestational age, elevated IL-6 approached significance as a predictor for worse developmental outcome (OR 1.025 ). Pathological evidence of maternal malperfusion and worse outcomes were noted in early preterm, although the sample size was small. When chronic villitis was present (N = 5), higher maternal levels of IL-6 (N = 3; 60%) were usually present rather than in fetal cord blood. Although only three cases of histologic fetal inflammatory response were seen, both IL-6 and IL-8 were elevated in the fetal cord blood (N = 2; 67%), but not elevated in maternal samples.
The authors concluded that their study supports the distinction that 32-weeks gestational age (‘moderate preterm) is a turning point for improved neurological outcomes. They found that cranial ultrasounds were unhelpful in predicting risk in this pre-eclamptic population. The data suggest that maternal placental malperfusion at earlier gestational age may be an underlying factor associated with poor neurological outcomes, although more robust studies are warranted. Neither elevated cytokines nor “male disadvantage” was associated with adverse neurological outcomes. The study was published on November 15, 2021 in the journal PloS One.
Related Links:
University of Colorado Anschutz Medical Campus
Luminex Corp
Latest Immunology News
- Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Channels
Clinical Chemistry
view channel
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
Long-Read DNA Test Improves Diagnosis of Rare Genetic Diseases
Rare diseases affect up to 400 million people worldwide, yet many remain difficult to diagnose and often require years-long diagnostic journeys. Approximately 80% have a genetic basis, but conventional... Read more
At-Home Urine Collection Kit Enables High-Throughput STI Screening
Sexually transmitted infection screening often hinges on access to private, convenient sample collection and timely laboratory processing. Many patients face logistical or privacy barriers that limit participation... Read more
Noninvasive Sequencing Test Approaches Invasive Genome Sequencing for Prenatal Screening
Prenatal genetic evaluation guides obstetric care, but standard diagnostics often require invasive procedures that carry risks, stress, and access barriers. Noninvasive prenatal testing (NIPT) has expanded... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreMicrobiology
view channel
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more
New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
Louse-borne relapsing fever is a neglected infection caused by Borrelia recurrentis and spread by body lice, with untreated mortality reaching up to 20%. Recurrent febrile episodes complicate recognition... Read more
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies
Predicta Biosciences (Cambridge, MA, USA) and CIMA LAB Diagnostics at Clínica Universidad de Navarra (Pamplona, Spain) have entered an agreement to provide a joint service that combines CIMA LAB’s flow... Read more








